These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11524774)

  • 1. [Gene therapy of malignant hematologic diseases].
    Porkka K
    Duodecim; 1998; 114(12):1275-85. PubMed ID: 11524774
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene therapy of hematologic malignancies.
    Wierda WG; Kipps TJ
    Semin Oncol; 2000 Oct; 27(5):502-11. PubMed ID: 11049018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for hematological malignancies.
    Schmidt-Wolf GD; Schmidt-Wolf IG
    Clin Exp Med; 2003 May; 3(1):4-14. PubMed ID: 12748873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams.
    Cheson BD
    J Clin Oncol; 2005 Sep; 23(26):6283-4. PubMed ID: 16155010
    [No Abstract]   [Full Text] [Related]  

  • 5. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell therapy for malignant diseases.
    Shapira MY; Hai AA; Tsirigotis P; Resnick IB; Or R; Slavin S
    Ann Med; 2007; 39(6):465-73. PubMed ID: 17852026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
    Pollack SM; O'Connor TP; Hashash J; Tabbara IA
    Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards immunogene therapy of hematological malignancies.
    Ivanov R; Hagenbeek A; Ebeling S
    Exp Hematol; 2006 Mar; 34(3):251-63. PubMed ID: 16543059
    [No Abstract]   [Full Text] [Related]  

  • 11. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of gene transfer in hematologic malignancy.
    Brenner MK
    Recent Results Cancer Res; 1998; 144():60-9. PubMed ID: 9304708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
    Fuchs EJ; Whartenby KA
    Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hematopoietic malignancies and gene therapy].
    Ozawa K
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer for activation of CMV specific T cells.
    André-Schmutz I; Dal Cortivo L; Hamel Y; Cavazzana-Calvo M
    Hum Immunol; 2004 May; 65(5):565-70. PubMed ID: 15172458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic manipulation of drug sensitivity in haematopoietic cells.
    Southgate T; Fairbairn LJ
    Expert Rev Mol Med; 2004 Aug; 6(18):1-24. PubMed ID: 15387894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suicide gene therapy and the control of graft-vs-host disease.
    Introna M; Rambaldi A
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):453-63. PubMed ID: 15498716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 20. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
    van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
    Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.